[HTML][HTML] Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa, BC Cho… - European Journal of …, 2020 - Elsevier
Background In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa… - European Journal of …, 2020 - ejcancer.com
Background In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
[PDF][PDF] Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa, BC Cho… - European Journal of …, 2020 - core.ac.uk
Background: In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
[PDF][PDF] Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa… - European Journal of …, 2020 - kimia-pharma.co
Background: In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
NB Leighl, N Karaseva, K Nakagawa… - European Journal of …, 2019 - europepmc.org
Background In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa… - … Journal of Cancer, 2020 - yonsei.elsevierpure.com
Background: In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
[PDF][PDF] Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa, BC Cho… - EUROPEAN JOURNAL …, 2019 - iris.unito.it
For patients with advanced non-small-cell lung cancer (NSCLC) and sensitizing epidermal
growth factor receptor mutations (EGFRm), the introduction of targeted therapy with EGFR …
growth factor receptor mutations (EGFRm), the introduction of targeted therapy with EGFR …
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa, BC Cho… - European Journal of …, 2020 - elibrary.ru
Background: In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa… - … journal of cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Background In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
[PDF][PDF] Patient-reported outcomes from FLAURA: Osimertinib TS versus erlotinib or gefitinib in patients with EGFR-updates mutated advanced non-small-cell lung …
BC Cho, JE Gray, T Hovey, A Walding - European Journal of Cancer, 2020 - iris.unito.it
For patients with advanced non-small-cell lung cancer (NSCLC) and sensitizing epidermal
growth factor receptor mutations (EGFRm), the introduction of targeted therapy with EGFR …
growth factor receptor mutations (EGFRm), the introduction of targeted therapy with EGFR …